Vanderbilt Clinical Neurosciences
How to Participate in Research
Patients interested in participating in stroke research studies can call our Neurology Clinical Research Coordinator, Diane Brown, RN, BSN, CCRP at (615) 936-0062.
Research on Acute Stroke Treatments
The treatment of acute stroke is a recent, rapidly evolving area of research that has already delivered succesful results. However, more needs to be done to further improve outcomes for patients. The Vanderbilt Stroke Center has been actively involved in research since 1992 and is currently managing these acute stroke trials:
CLEAR III- Intraventricular Thrombolysis Clinical Trial: Intraventricular hemorrhage (IVH) is sudden bleeding into the ventricular system of the brain, often the result of intracerebral hemorrhage. This complication of hemorrhagic stroke has a mortality rate of 60-80% and only about 10% of patients recover with a good outcome.
CLEAR III is a 500-patient Phase-III randomized clinical trial using a recombinant tissue plasminogen activator (Activase) to quickly remove this blood from the ventricles. It is the hope of the over 70 academic medical centers in this international clinical trial that this may prove to be a better way to treat this brain injury.
POINT: Seeks to determine whether the blood-thinning drug clopidogrel (aka Plavix) is effective in preventing strokes, heart attacks and vascular death in patients who have had minor strokes.
Time Window: 0-12 hours
Research in Stroke Prevention
The prevention of stroke has been another success story. Primary stroke prevention with exercise, diet, smoking cessation and treatment of hypertension is important in all patients. Medical treatments to prevent stroke include combination anti-hypertensive medications, cholesterol management, carotid surgery, anticoagulation with warfarin for patients with cardiac sources of emboli to the brain, and antiplatelet therapy for patients with TIA or minor stroke.
Research in Pediatric Stroke
Thrombolysis in Pediatric Stroke (TIPS): (TIPS) is a five-year multi-center international safety and dose-finding study of intravenous (IV) tPA in children with acute ischemic stroke to determine the maximal safe dose of intravenous (IV) tPA among three doses (0.75. 0.9, 1.0 mg/kg) for children age 2-17 years within 4.5 hours from onset of acute ischemic stroke. Time Window 0 – 4.5 hours
tPA Dose Calculation Form
Consent Form: Children under 6
Consent Form: Children ages 7-11
Consent Form: Children ages 12-17
Consent Form: Parents
Research for Patients with Past Strokes
Dysport Lower Limb Study: This trial will test whether the drug Dysport, which is used in certain cosmetic dermatology procedures, is effective in improving calf muscle tone in patients who have suffered stroke or traumatic brain injury.
Other Areas of Stroke Research
There are several basic science (done in the laboratory) research projects ran and/or coordinated by Dr. McLaughlin, many sponsored by the NIH or the department of Defense, among them:
- Cellular Mechanisms of Preconditioning Neuroprotection: The goal of this translational research program is to develop an in-depth understanding of the events that protect neurons from stroke in order to improve neuroprotective therapies.
- BOLD: Investigating the brain perfusion in patients with intracranial stenosis.
For information or scheduling for the BOLD study, contact:
Practice Manager, Interventional Neuroradiology
Fax: (615) 322-6889
Institute of Imaging Science
Also, with our Neurointerventional team, the Vanderbilt Stroke Center is involved in the application of angioplasty and stent placement in patients with TIA and stroke secondary to arterial stenosis in the carotid or vertebrobasilar vessels, especially those in which standard surgical techniques are not applicable.